FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137357003> ?p ?o ?g. }

• W2137357003 endingPage "4292" @default.
• W2137357003 startingPage "4284" @default.
• W2137357003 abstract "Purpose Sonic hedgehog (SHH), an activating ligand of smoothened (SMO), is overexpressed in > 70% of pancreatic cancers (PCs). We investigated the impact of vismodegib, an SHH antagonist, plus gemcitabine (GV) or gemcitabine plus placebo (GP) in a multicenter phase Ib/randomized phase II trial and preclinical PC models. Patients and Methods Patients with PC not amenable to curative therapy who had received no prior therapy for metastatic disease and had Karnofsky performance score ≥ 80 were enrolled. Patients were randomly assigned in a one-to-one ratio to GV or GP. The primary end point was progression-free-survival (PFS). Exploratory correlative studies included serial SHH serum levels and contrast perfusion computed tomography imaging. To further investigate putative biologic mechanisms of SMO inhibition, two autochthonous pancreatic cancer models (Kras G12D ; p16/p19 fl/fl ; Pdx1-Cre and Kras G12D ; p53 R270H/wt ; Pdx1-Cre) were studied. Results No safety issues were identified in the phase Ib portion (n = 7), and the phase II study enrolled 106 evaluable patients (n = 53 in each arm). Median PFS was 4.0 and 2.5 months for GV and GP arms, respectively (95% CI, 2.5 to 5.3 and 1.9 to 3.8, respectively; adjusted hazard ratio, 0.81; 95% CI, 0.54 to 1.21; P = .30). Median overall survival (OS) was 6.9 and 6.1 months for GV and GP arms, respectively (95% CI, 5.8 to 8.0 and 5.0 to 8.0, respectively; adjusted hazard ratio, 1.04; 95% CI, 0.69 to 1.58; P = .84). Response rates were not significantly different. There were no significant associations between correlative markers and overall response rate, PFS, or OS. Preclinical trials revealed no significant differences with vismodegib in drug delivery, tumor growth rate, or OS in either model. Conclusion The addition of vismodegib to gemcitabine in an unselected cohort did not improve overall response rate, PFS, or OS in patients with metastatic PC. Our preclinical and clinical results revealed no statistically significant differences with respect to drug delivery or treatment efficacy using vismodegib." @default.
• W2137357003 created "2016-06-24" @default.
• W2137357003 creator A5003826371 @default.
• W2137357003 creator A5011233983 @default.
• W2137357003 creator A5013408333 @default.
• W2137357003 creator A5017065880 @default.
• W2137357003 creator A5020012126 @default.
• W2137357003 creator A5021535454 @default.
• W2137357003 creator A5036964240 @default.
• W2137357003 creator A5038171309 @default.
• W2137357003 creator A5040110214 @default.
• W2137357003 creator A5046488650 @default.
• W2137357003 creator A5047818279 @default.
• W2137357003 creator A5048973199 @default.
• W2137357003 creator A5060130258 @default.
• W2137357003 creator A5064887537 @default.
• W2137357003 creator A5066487010 @default.
• W2137357003 creator A5073785005 @default.
• W2137357003 creator A5075327015 @default.
• W2137357003 creator A5077068949 @default.
• W2137357003 creator A5082691013 @default.
• W2137357003 creator A5082874698 @default.
• W2137357003 creator A5084071593 @default.
• W2137357003 creator A5084809433 @default.
• W2137357003 creator A5088131964 @default.
• W2137357003 creator A5090156519 @default.
• W2137357003 date "2015-12-20" @default.
• W2137357003 modified "2023-10-17" @default.
• W2137357003 title "Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer" @default.
• W2137357003 cites W1931508686 @default.
• W2137357003 cites W1965431780 @default.
• W2137357003 cites W1966643394 @default.
• W2137357003 cites W1969925021 @default.
• W2137357003 cites W1971298987 @default.
• W2137357003 cites W1978221150 @default.
• W2137357003 cites W1978683990 @default.
• W2137357003 cites W1981104423 @default.
• W2137357003 cites W1992995822 @default.
• W2137357003 cites W1996912024 @default.
• W2137357003 cites W2002355858 @default.
• W2137357003 cites W2002683064 @default.
• W2137357003 cites W2010237337 @default.
• W2137357003 cites W2012084975 @default.
• W2137357003 cites W2018644553 @default.
• W2137357003 cites W2023040415 @default.
• W2137357003 cites W2027491005 @default.
• W2137357003 cites W2030199762 @default.
• W2137357003 cites W2031211581 @default.
• W2137357003 cites W2034893372 @default.
• W2137357003 cites W2050569781 @default.
• W2137357003 cites W2056041663 @default.
• W2137357003 cites W2062038881 @default.
• W2137357003 cites W2079067257 @default.
• W2137357003 cites W2081170157 @default.
• W2137357003 cites W2087896991 @default.
• W2137357003 cites W2101037339 @default.
• W2137357003 cites W2106711992 @default.
• W2137357003 cites W2107441200 @default.
• W2137357003 cites W2115898240 @default.
• W2137357003 cites W2117774671 @default.
• W2137357003 cites W2120010339 @default.
• W2137357003 cites W2121017846 @default.
• W2137357003 cites W2128095147 @default.
• W2137357003 cites W2134355392 @default.
• W2137357003 cites W2136799968 @default.
• W2137357003 cites W2137508065 @default.
• W2137357003 cites W2139499843 @default.
• W2137357003 cites W2144025124 @default.
• W2137357003 cites W2146905485 @default.
• W2137357003 cites W2151253787 @default.
• W2137357003 cites W2154953378 @default.
• W2137357003 cites W2158134441 @default.
• W2137357003 cites W2161817637 @default.
• W2137357003 cites W2165480504 @default.
• W2137357003 cites W2166773454 @default.
• W2137357003 cites W2171203391 @default.
• W2137357003 cites W2188515569 @default.
• W2137357003 cites W2279876539 @default.
• W2137357003 cites W2303626367 @default.
• W2137357003 cites W2316089511 @default.
• W2137357003 cites W2384781988 @default.
• W2137357003 doi "https://doi.org/10.1200/jco.2015.62.8719" @default.
• W2137357003 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4678179" @default.
• W2137357003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26527777" @default.
• W2137357003 hasPublicationYear "2015" @default.
• W2137357003 type Work @default.
• W2137357003 sameAs 2137357003 @default.
• W2137357003 citedByCount "399" @default.
• W2137357003 countsByYear W21373570032016 @default.
• W2137357003 countsByYear W21373570032017 @default.
• W2137357003 countsByYear W21373570032018 @default.
• W2137357003 countsByYear W21373570032019 @default.
• W2137357003 countsByYear W21373570032020 @default.
• W2137357003 countsByYear W21373570032021 @default.
• W2137357003 countsByYear W21373570032022 @default.
• W2137357003 countsByYear W21373570032023 @default.
• W2137357003 crossrefType "journal-article" @default.
• W2137357003 hasAuthorship W2137357003A5003826371 @default.

• next